Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced
Links shared publicly online about this topic.
- 1,407total visits
Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplasti
View full resource at news-medical.net
Tags: Genetic, Cancer, Chemotherapy, Lymphoma, Hodgkin Lymphoma, Pharma, Clinical Trial, Oncology
Most Recently Shared on February 4, 2010 at 6:52 am By:
Oncology News: Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced: Seattle... http://bit.ly/abRd8s
Seattle Genetics And Millennium Announce Initiation Of Phase I Combination Clinical Trial Of Brentuximab Vedotin For Front-line Hodgkin Lymphoma
medicalnewstoday.com — “Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SG” View full resource at medicalnewstoday.com
Most Recently Shared on February 5, 2010 at 2:37 am By:
Seattle Genetics And Millennium Announce Initiation Of Phase I Combination Clinical Trial Of Brentuximab Vedotin For .. http://bit.ly/cz7LNj
Advertisement
